<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730481</url>
  </required_header>
  <id_info>
    <org_study_id>KX-ORAX-004</org_study_id>
    <nct_id>NCT02730481</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies</brief_title>
  <official_title>A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athenex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athenex, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, safety study. Eligible subjects will be adults with&#xD;
      advanced malignancies. The study includes a pretreatment and treatment phase. The&#xD;
      pretreatment phase consists of screening and baseline periods. The treatment phase consists&#xD;
      of 4-week treatment periods and a follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of Oraxol</measure>
    <time_frame>20 weeks</time_frame>
    <description>The highest dose at which no more than 1 of 6 subjects experience a dose-limiting toxicity (DLT) during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumor response</measure>
    <time_frame>At baseline and every 8 weeks through study completion, approximately 24 months</time_frame>
    <description>RECIST v1.1 criteria defined as complete response, partial response, stable disease or progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with abnormal laboratory values and/or adverse events that are related to treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of Participants with abnormal laboratory values and/or adverse events that are related to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of Oraxol in the blood stream</measure>
    <time_frame>3 weeks</time_frame>
    <description>The measurement of Oraxol levels in the blood stream over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The recommended Phase 2 dose of paclitaxel as Oraxol</measure>
    <time_frame>24 months</time_frame>
    <description>The totality of information from the number of participants that reach the MTD (outcome #1), the number of participants that experience abnormal laboratory values and/or adverse events that are related to treatment (outcome #3), and the amount of Oraxol in the blood stream in participants (outcome #4)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ORAXOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules&#xD;
Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oraxol</intervention_name>
    <description>Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.</description>
    <arm_group_label>ORAXOL</arm_group_label>
    <other_name>Paclitaxel and HM30181AK-US</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. ≥18 years of age&#xD;
&#xD;
          3. Histologically or cytologically confirmed solid tumor that is metastatic or&#xD;
             unresectable and for which standard curative or palliative measures do not exist or&#xD;
             are no longer effective&#xD;
&#xD;
          4. Measurable disease as per RECIST v1.1 criteria&#xD;
&#xD;
          5. Adequate hematologic status as demonstrated by not requiring transfusion support or&#xD;
             granulocyte-colony stimulating factor (G-CSF) to maintain: ANC ≥1500 cells/mm3,&#xD;
             Platelet count ≥100 x 109/L, Hemoglobin ≥9 g/dL&#xD;
&#xD;
          6. Adequate liver function as demonstrated by:Total bilirubin of ≤1.5 mg/dL or ≤2.0 mg/dL&#xD;
             for subjects with liver metastasis, Alanine aminotransferase ≤3 x upper limit of&#xD;
             normal (ULN) or ≤5 x ULN if liver metastasis is present, Alkaline phosphatase ≤3 x ULN&#xD;
             or ≤5 x ULN if bone or liver metastasis is present&#xD;
&#xD;
          7. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN or creatinine&#xD;
             clearance calculation ≥60 mL/min as calculated by the Cockcroft and Gault formula&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          9. Life expectancy of at least 3 months&#xD;
&#xD;
         10. Women must be postmenopausal (&gt;12 months without menses) or surgically sterile (ie, by&#xD;
             hysterectomy and/or bilateral oophorectomy) or must be using effective contraception&#xD;
             (ie, oral contraceptives, intrauterine device, double barrier method of condom and&#xD;
             spermicide) and agree to continue use of contraception for 30 days after their last&#xD;
             dose of study drug.&#xD;
&#xD;
         11. Sexually active male subjects must use a barrier method of contraception during the&#xD;
             study and agree to continue the use of male contraception for at least 30 days after&#xD;
             the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or&#xD;
             previous investigational products (IPs)&#xD;
&#xD;
          2. Received IPs within 30 days or 5 half lives of the first study dosing day&#xD;
&#xD;
          3. Are currently receiving other medications or radiation intended for the treatment of&#xD;
             their malignancy&#xD;
&#xD;
          4. Women of childbearing potential who are pregnant or breastfeeding&#xD;
&#xD;
          5. Currently taking a concomitant medication&#xD;
&#xD;
          6. Require therapeutic use of anticoagulation medications&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, myocardial infarction within the last&#xD;
             6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease&#xD;
             requiring oxygen, known bleeding disorders, or any concomitant illness or social&#xD;
             situation that would limit compliance with study requirements&#xD;
&#xD;
          8. Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI&#xD;
             disease or other medical condition that, in the opinion of the investigator may&#xD;
             interfere with oral drug absorption&#xD;
&#xD;
          9. History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type&#xD;
             reaction to Cremophor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E D Kramer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kinex Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp;Research Center @ UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

